FDA OKs 23andMe to sell disease risk genetic tests

Cara Livernois | | Health Exec | Economics

In a first for the U.S. Food and Drug Administration (FDA), the genetic testing company 23andMe is being given permission to sell genetic tests for disease risks.

23andMe, known for their ancestral genetic tests, will now be able to sell genetics tests capable to analyzing a person disease risk for developing 10 different conditions including Parkinson’s and Alzheimer’s. The decision is set to open the genetic testing market to other companies, increasing the rate of at-home testing for risk of disease development.

Read the full story by clicking below:

F.D.A. Will Allow 23andMe to Sell Genetic Tests for Disease Risk to Consumers

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Report: 44% of adults in the U.S. are uninsured or underinsured
Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation
Cardiologist demand is on the rise—can hospitals keep up?
Cardinal Health scoops up two companies for $3.9B
UnitedHealth defends $3.3B Amedisys acquisition
DOJ sues to block UnitedHealth’s $3.3B acquisition of home health giant

Around the web

Cardiovascular Business
Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”